Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Gossamer Bio closes $230mm Series B round

Executive Summary

Gossamer Bio Inc. raised $230mm through its Series B round led by Hillhouse Capital. New buyers Invus, a subsidiary of the Abu Dhabi Investment Authority, the Baupost Group, and Polaris Partners were joined by returning backers Arch Venture Partners and Omega Funds. Gossamer is developing treatments for autoimmune, GI, allergy/inflammation, and immuno-oncology indications and will use the funds to advance its candidates through early- and mid-stage trials.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies